235 related articles for article (PubMed ID: 8721923)
21. Parkinson's disease: drug therapy.
Oertel WH; Quinn NP
Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
[TBL] [Abstract][Full Text] [Related]
22. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias.
Mark MH; Sage JI
Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565
[TBL] [Abstract][Full Text] [Related]
23. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
24. Parkinson's disease in the elderly: current management strategies.
Aminoff MJ
Geriatrics; 1987 Jul; 42(7):31-7. PubMed ID: 3110015
[TBL] [Abstract][Full Text] [Related]
25. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
Stryjer R; Klein C; Treves TA; Rabey JM
Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
[TBL] [Abstract][Full Text] [Related]
26. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
27. Superoxide dismutase activity in early and advanced Parkinson's disease.
Bostantjopoulou S; Kyriazis G; Katsarou Z; Kiosseoglou G; Kazis A; Mentenopoulos G
Funct Neurol; 1997; 12(2):63-8. PubMed ID: 9238339
[TBL] [Abstract][Full Text] [Related]
28. Selegiline slows the progression of the symptoms of Parkinson disease.
Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
[TBL] [Abstract][Full Text] [Related]
29. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen EH; Myllylä V
Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
31. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
32. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
Cedarbaum JM; Toy LH; Green-Parsons A
Clin Neuropharmacol; 1991 Jun; 14(3):228-34. PubMed ID: 1906374
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
34. Single vs multiple daily dosing of aminoglycosides.
Newton W
J Fam Pract; 1996 May; 42(5):456-7. PubMed ID: 8642359
[No Abstract] [Full Text] [Related]
35. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Segovia G; Mora F; Crossman AR; Brotchie JM
Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
[TBL] [Abstract][Full Text] [Related]
36. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
Broussolle E
Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845
[No Abstract] [Full Text] [Related]
37. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
[TBL] [Abstract][Full Text] [Related]
38. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.
Counsell C
BMJ; 1998 Dec; 317(7172):1586. PubMed ID: 9836669
[No Abstract] [Full Text] [Related]
39. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
Amato L; Nava L; Rizzo M; Piccoli F
Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
[No Abstract] [Full Text] [Related]
40. Role of selegiline as initial monotherapy in early Parkinson's disease.
Bhatia M; Jain S; Maheshwari MC
J Assoc Physicians India; 1994 Jan; 42(1):30-2. PubMed ID: 7836244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
